Abstract: The present application provides a compound dry powder inhalant, comprising baicalin, ambroxol hydrochloride, L-leucine and phosphate, wherein based on a mass of the compound dry powder inhalant, L-leucine accounts for 0-50%, phosphate accounts for 15-35%, and a total mass of baicalin and ambroxol hydrochloride accounts for 15-85%, and wherein a mass ratio of baicalin to ambroxol hydrochloride is 1:0.2 to 2. The compound dry powder inhalant has a Dv90?5 ?m. The drug combination of baicalin and ambroxol hydrochloride can effectively reduce inflammation and oxidative damage in lung tissue, alleviate pulmonary edema and histopathological changes, and reduce pulmonary dysfunction and pulmonary fibrosis.

Abstract: Embodiments of the present invention provide a system (100) for providing targeted cue delivery to regulate a gait of a user comprising a first cue delivery device (131) configured to provide somatosensory stimulation to a first leg of the user, a second cue delivery device (132) configured to provide somatosensory stimulation to a second leg of the user, one or more inertial sensors (121, 122) configured to output movement data indicative of the gait of the user, and a controller (110) configured to receive the movement data from the one or more inertial sensors (121, 122), determine a cue pattern for each of the first and second cue delivery devices (131, 132) independence on the movement data, and output a respective control signal (135, 136) to control each of the first and second cue delivery devices (135, 136) to provide stimulation according to the cue pattern.

Abstract: Provided are a tumour antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding same; a nucleic acid construct, an expression vector, and a host cell comprising the encoding nucleic acid; and an antigen presenting cell presenting the tumour antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a tumour antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding same; a nucleic acid construct, an expression vector, and a host cell comprising the encoding nucleic acid; and an antigen presenting cell presenting the tumour antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.

Abstract: The disclosure relates to a modifier composition for polyolefin, a polyolefin for packaging and a flexible packaging film. The disclosure relates to a modifier composition for polyolefin, including: (A) nano-silicon dioxide; (B) polyvinyl alcohol; (C) acrylic copolymer; and (D) Ethylene-Vinyl Acetate (EVA) copolymer. The disclosure also relates to a polyolefin for packaging, including: a polyolefin resin and a modifier composition of the polyolefin provided by the disclosure. The disclosure also relates to a flexible packaging film, of which at least a part is made of the polyolefin for packaging of the disclosure. The modifier composition of the disclosure can obviously improve the performance in the aspect of reducing residue of solvent in the polyolefin flexible packaging film.

Abstract: The disclosure relates to a modifier composition for polyolefin, a polyolefin for packaging and a flexible packaging film. The disclosure relates to a modifier composition for polyolefin, including: (A) nano-silicon dioxide; (B) polyvinyl alcohol; (C) acrylic copolymer; and (D) Ethylene-Vinyl Acetate (EVA) copolymer. The disclosure also relates to a polyolefin for packaging, including: a polyolefin resin and a modifier composition of the polyolefin provided by the disclosure. The disclosure also relates to a flexible packaging film, of which at least a part is made of the polyolefin for packaging of the disclosure. The modifier composition of the disclosure can obviously improve the performance in the aspect of reducing residue of solvent in the polyolefin flexible packaging film.

Abstract: An electronic alarm clock connected to one or more networks comprises: a network communications device, wherein the network device receives content from the networks; a touch screen; one or more speakers; and a local storage device, wherein a clock function is provided, wherein an alarm function is provided that plays user specified content at a user specified time on said screen and the speakers, and wherein a physical button is disposed on the clock to manage the alarm function during an alarm.

Abstract: The present utility model proposes an impulse generator for driving an electronic ballast of a gas discharge lamp, the electronic ballast includes a resonance ignition circuit, characterized in that the impulse generator comprises: a micro-controller for generating a clock frequency signal, a logical time sequence control signal and a control voltage signal; a voltage controlled oscillator, coupled to the micro-controller, for receiving the logical time sequence control signal and the control voltage signal to generate oscillation and output a voltage controlled oscillating frequency signal; a phase comparator for receiving the clock frequency signal and the voltage controlled oscillating frequency signal to perform a logical exclusive-OR operation and output an impulse signal of corresponding frequency, thereby driving the resonance ignition circuit to generate a resonance voltage. In addition, the utility model also proposes an over-voltage protection circuit used for the electronic ballast.